Vestal Point Capital, LP Reports New 9.9% Stake in Aprea Therapeutics, Inc. via Warrants

On May 15, 2026, Vestal Point Capital, LP and Ryan Wilder filed a Schedule 13G disclosing a new 9.9% stake in Aprea Therapeutics, Inc. (APRE). The reporting persons beneficially own 22,654,832 shares of common stock, which includes 22,304,832 shares issuable upon the exercise of common stock purchase warrants and pre-funded warrants. The filing specifies that these warrants are subject to a 9.99% blocker, preventing the reporting persons from exercising them to a degree that would result in ownership exceeding 9.99% of the outstanding shares. Consequently, while the total shares underlying the warrants are reported, the actual exercisable amount is capped by this provision. The reporting persons include Vestal Point Capital, LP, acting as the investment manager for a fund and a managed account, and Ryan Wilder, the Chief Investment Officer and Managing Partner. The securities were acquired in the ordinary course of business and not for the purpose of influencing control over the issuer. The ownership percentage is calculated based on 11,452,452 shares outstanding as of March 16, 2026.